SCO-792, an enteropeptidase inhibitor, attenuated renal and hepatic cyst progression in a mouse model of autosomal dominant polycystic kidney disease

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/2b4be7f01c9d5062c2e08bfb1e74c2dd.pdf
SCO-792, an enteropeptidase inhibitor, attenuated renal and hepatic cyst progression in a mouse model of autosomal dominant polycystic kidney disease

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Takuro
Kawamura
Takuro Kawamura takuhuku@gmail.com Hokkaido University Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Sapporo Japan *
Fumihiko Hattanda fumihiko_417@yahoo.co.jp Hokkaido University Hospital Department of Hemodialysis and Apheresis Sapporo Japan -
Shun Takenaka shunt0615@gmail.com Hokkaido University Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Sapporo Japan -
Kanako Watanabe-Kusunoki wata.kanako@gmail.com Hokkaido University Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Sapporo Japan -
Jun Sugama jun.sugama@scohia.com SCOHIA PHARMA, Inc none Fujisawa Japan -
Yusuke Moritoh yusuke.moritoh@scohia.com SCOHIA PHARMA, Inc none Fujisawa Japan -
Masanori Watanabe masanori.watanabe@scohia.com SCOHIA PHARMA, Inc none Fujisawa Japan -
Daigo Nakazawa daigo-na@med.hokudai.ac.jp Hokkaido University Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Sapporo Japan -
Tatsuya Atsumi at3tat@med.hokudai.ac.jp Hokkaido University Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Sapporo Japan -
Saori Nishio saorin@med.hokudai.ac.jp Hokkaido University Hospital Department of Hemodialysis and Apheresis Sapporo Japan -
-
-
-
-
-